Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,080.00
-50.00 (-0.97%)
At close: Sep 11, 2026

Kyung Dong Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
201,120196,273193,936162,674182,718177,611
Other Revenue
-0-0-0--0-
201,120196,273193,936162,674182,718177,611
Revenue Growth
3.46%1.21%19.22%-10.97%2.88%2.18%
Cost of Revenue
79,00579,17279,57173,33186,80879,528
Gross Profit
122,115117,101114,36589,34495,91098,082
Selling, General & Admin
100,02699,91798,62186,47170,60268,447
Research & Development
8,3297,79311,12013,82712,61810,537
Amortization of Goodwill & Intangibles
416.6326.24341.9352.232.76.99
Other Operating Expenses
677.04531.12599.2412,4692,4341,603
Operating Expenses
110,343109,435111,741114,29887,59882,324
Operating Income
11,7727,6662,624-24,9558,31215,758
Interest Expense
-1,717-1,775-2,159-1,596-867.87-65.82
Interest & Investment Income
2,6342,6872,5183,1702,7022,610
Earnings From Equity Investments
1,944-66.38503.273,08311,387-155.57
Currency Exchange Gain (Loss)
226.9111.7266.84-5.73-40.15161.08
Other Non Operating Income (Expenses)
-891.91-745.79-192.72-410.62-1,701-736.18
EBT Excluding Unusual Items
13,9687,7783,561-20,71419,79217,572
Gain (Loss) on Sale of Investments
5,088-748.831,7652,149-1,709786.97
Gain (Loss) on Sale of Assets
2,4132,09492.3961.03-142.2773.23
Asset Writedown
-223.47--197.41---
Pretax Income
21,2469,1235,221-18,50317,94118,432
Income Tax Expense
3,516672.05-226.722,2275,8285,806
Earnings From Continuing Operations
17,7308,4515,448-20,73012,11312,627
Minority Interest in Earnings
100.6377.921.8622.7748.445.13
Net Income
17,8318,5295,470-20,70812,16112,672
Net Income to Common
17,8318,5295,470-20,70812,16112,672
Net Income Growth
353.56%55.93%---4.03%1.71%
Shares Outstanding (Basic)
272727272728
Shares Outstanding (Diluted)
282727272728
Shares Change
5.40%0.72%-0.70%-0.27%-1.14%12.18%
EPS (Basic)
650.59316.02203.00-763.17446.96460.42
EPS (Diluted)
647.85315.00203.00-763.17446.96460.42
EPS Growth
330.83%55.17%---2.92%-9.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
4,606-1,460-15,692-6,322-11,6498,496
Free Cash Flow Per Share
167.14-53.82-582.38-232.98-428.12308.70
Dividend Per Share
----400.000500.000
Dividend Growth
-----20.00%0%
Gross Margin
60.72%59.66%58.97%54.92%52.49%55.22%
Operating Margin
5.85%3.91%1.35%-15.34%4.55%8.87%
Profit Margin
8.87%4.35%2.82%-12.73%6.66%7.13%
Free Cash Flow Margin
2.29%-0.74%-8.09%-3.89%-6.38%4.78%
EBITDA
15,74911,3448,044-19,10615,01622,770
EBITDA Margin
7.83%5.78%4.15%-11.74%8.22%12.82%
D&A For EBITDA
3,9773,6785,4205,8496,7047,011
EBIT
11,7727,6662,624-24,9558,31215,758
EBIT Margin
5.85%3.91%1.35%-15.34%4.55%8.87%
Effective Tax Rate
16.55%7.37%--32.49%31.50%
Advertising Expenses
-2,9525,8575,24810,3159,603